The negotiations list is here; Amgen, Horizon clear FTC hurdle; Fall biotech IPOs?; Novo buys biotech partner in obesity; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
If you get the Endpoints Weekly in your email inbox, you may notice that we have a new look. Between the selection of drugs to go under Medicare price negotiations and the FTC’s settlement with Amgen and Horizon, it has been a historical week with sweeping implications for biopharma. And there’s a lot more — see if you missed any major news.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.